As per DelveInsight’s assessment, globally, about 20+ key pharma and biotech companies are working in the Frontotemporal Dementia therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
DelveInsight’s “Frontotemporal Dementia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Frontotemporal Dementia market trends in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Frontotemporal Dementia Disease Overview
Frontotemporal dementia (FTD) is an umbrella term for a diverse group of uncommon disorders that primarily affect the frontal and temporal lobes of the brain areas. In this disorder, portions of these lobes shrink (atrophy). The degeneration of the frontotemporal lobe is primarily triggered due to protein involvement in TDP43 and tau, which directly outbreaks damage on the temporal and frontal lobes of the brain.
To redress the current issues, the companies are currently working on novel therapies to meet the needs of the current market. Companies are primarily focused on adapting to the latest technological advancement in drug manufacturing and offering drugs with reduced side effects for frontotemporal dementia treatment.
The research and development in advanced gene therapy, particularly in the field of neurodegeneration, is offering the manufacturers involved in the frontotemporal dementia treatment market a prime scope for competition.
Frontotemporal Dementia Market Key Facts
- Among the FTD patients, males show a higher proportion of prevalence of FTD as compared to females in the 7MM
- As per the National Organization for Rare Disorder 2019, Frontotemporal degeneration is estimated to affect about 50,000–60,000 people in the United States.
- As per the study conducted by Juan Joseph Young et al. 2017, in the USA, the prevalence of FTD between the ages of 45–65 years ranged from 15 to 22 per 100,000 people, with incidence estimates ranging from 2.7 to 4.1 per 100,000 members in the same age range.
The market outlook section of the report helps to understand the historical, current, and forecasted Frontotemporal Dementia market size by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.
The report gives a thorough detail of key trends, ongoing developments, and growth opportunities of each marketed and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders in the domain.
Get the PDF Sample of the Report @ https://www.delveinsight.com/sample-request/frontotemporal-dementia-market
Frontotemporal Dementia Epidemiology
The epidemiology section covers insights into the historical and current Frontotemporal Dementia patient pool and forecasted trends for every seven major markets from 2019 to 2032.
It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Discover more about the epidemiological segmentation @ https://www.delveinsight.com/sample-request/frontotemporal-dementia-market
Frontotemporal Dementia Drugs Uptake and Key Market Players
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Frontotemporal Dementia market or expected to get launched in the market during the study period. The analysis covers the drug uptake, patient uptake by therapies, and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Frontotemporal Dementia Pipeline Development Activities and provides valuable insights about different therapeutic candidates in various stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent development such as collaborations, acquisitions, mergers, licensing patent details, and other information.
Key Developments in the Frontotemporal Dementia Therapeutics Market
Companies across the globe are working toward the development of new treatment therapies for frontotemporal dementia, but few companies have made it to the clinical stage of development. Recent advances also suggest that there is an array of potential novel therapeutic targets, although data concerning their effectiveness are still preliminary.
In August 2022, Passage Bio, Inc. (Nasdaq: PASG) announced that the first patient had been dosed in the global Phase 1/2 upliFT-D clinical trial evaluating PBFT02, an adeno-associated virus (AAV)-delivery gene therapy for the treatment of patients with frontotemporal dementia (FTD) with granulin (GRN) mutations.
On April 27, 2022, AviadoBio announced that both the U.S. Food and Drug Administration (FDA) and the European Commission (EC) had granted orphan designation to its therapy, AVB-101, a one-time gene therapy for the treatment of frontotemporal dementia (FTD).
As per the DelveInsight, the dynamics of the Frontotemporal dementia market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending across the world, and also the expected launch of emerging therapies.
Learn how Frontotemporal Dementia Market will evolve by 2032 @ https://www.delveinsight.com/sample-request/frontotemporal-dementia-market
There are approx. 20+ key companies which are developing therapies for Frontotemporal Dementia. Currently, Alector has its Frontotemporal Dementia drug candidates in the most advanced stage of clinical development.
Some of the key companies in the Frontotemporal Dementia Therapeutics Market include:
- Prevail Therapeutics
- Passage Bio, Inc.
- TauRx Pharmaceuticals
- Wave Life Sciences Ltd.
- CAMP4 Therapeutics
- Coya Therapeutics
- DEEP GENOMICS
- Sangamo Therapeutics
- Arkuda Therapeutics
- Autifony Therapeutics
And many others
Frontotemporal Dementia Emerging Drugs Covered in the report include:
- PR 006 : Prevail Therapeutics
- Latozinemab : Alector
- PBFT 02 : Passage Bio
- WVE 004 : WaVe life Sciences
- EXO 050 : Coya Therapeutics
And many more
Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/frontotemporal-dementia-market
Table of Content
- Key Insights
- Executive Summary
- Frontotemporal Dementia Competitive Intelligence Analysis
- Frontotemporal Dementia Market Overview at a Glance
- Frontotemporal Dementia Disease Background and Overview
- Frontotemporal Dementia Patient Journey
- Frontotemporal Dementia Epidemiology and Patient Population
- Frontotemporal Dementia Treatment Algorithm, Current Treatment, and Medical Practices
- Frontotemporal Dementia Unmet Needs
- Key Endpoints of Frontotemporal Dementia Treatment
- Frontotemporal Dementia Marketed Products
- Frontotemporal Dementia Emerging Therapies
- Frontotemporal Dementia Seven Major Market Analysis
- Attribute Analysis
- Frontotemporal Dementia Market Outlook (7 major markets)
- Frontotemporal Dementia Access and Reimbursement Overview
- KOL Views on the Frontotemporal Dementia Market.
- Frontotemporal Dementia Market Drivers
- Frontotemporal Dementia Market Barriers
- DelveInsight Capabilities
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:-
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Assistant Manager, Marketing & IB
Phone No: +91-9650213330
Email: [email protected]
Request for Sample Copy of the Report at:
Latest Reports By DelveInsight:
“Frontotemporal Dementia Epidemiology Forecast” report delivers an in-depth understanding of the disease, historical and forecasted Frontotemporal Dementia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Frontotemporal Dementia Pipeline Insight, 2021 report by DelveInsight, outlays comprehensive insights of present clinical development scenario and growth prospects across the Frontotemporal Dementia market.